The trusted source for
healthcare information and
Candida auris is reportable nationwide this year, a move that should boost surveillance of an emerging pathogen that has been primarily confined in three states: New York, New Jersey, and Illinois.
The decision by the Council of State and Territorial Epidemiologists (CSTE) should put C. auris prevalence in better focus, allowing better tracking and benchmarking to measure prevention efforts. Below are some highlights and provisions from the CSTE report, which is available at: https://bit.ly/2FUtEoy.
The following factors referenced in the CSTE report are aimed at helping to identify “epidemiologic linkage” in patients:
The CSTE report also details the different classifications for clinical C. auris cases:
“Confirmed: Person with confirmatory laboratory evidence from a clinical specimen collected for the purpose of diagnosing or treating disease in the normal course of care. This includes specimens from sites reflecting invasive infection (e.g., blood, cerebrospinal fluid) and specimens from noninvasive sites such as wounds, urine, and the respiratory tract, where presence of C. auris may simply represent colonization and not true infection.
Probable: Person with presumptive laboratory evidence and evidence of epidemiologic linkage.
Suspect: Person with presumptive laboratory evidence and no evidence of epidemiologic linkage. Public health jurisdiction may consider stratifying clinical cases as invasive vs. noninvasive.”
Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health, Siemens, and CareDx. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.